In the wake of serious cuts which threaten public universities in Minnesota (largely aimed at the sprawling University of Minnesota system), is now the time to get involved in investing in knowledge capital? The U of M is being blamed for its lack of advancement in the field of bio-tech R&D. A report highlights the problems Minnesota has with maintaining an environment which fosters medical technical advancement and, more importantly in attracting those types of jobs — ones that can sustain a vibrant economy. Although the state is regarded as a pioneer in certain biotech spheres (notably cardiac devices), the report criticized Minnesota as focusing too much on a singular area and remaining stagnant. | LINK  | Report PDF LINK

Related Posts Within Doctor Pundit:

1. New Dementia Drug in Development Fails Initial Study Pfizer’s current research on a potential blockbuster anti-Alzheimer drug is...
2. Report: Minnesota’s Pharma Disclosure Laws Fail to Provide Audit Mechanism Policy wonks, regulatory agencies, legislators, and just about any interested...
3. Report: Branded Drug Use Sharply Down, Generics Way Up A healthcare informatics company issues a report today that I...
4. Report: 1M Young Adults Obtained Coverage in Q1 of 2011 The president can take some solace in a new report...
5. Report: Minnesota Achieves ‘A’ Rating in Palliative Care Provisions As a geriatrician, another reminder of the work that I...